Use of LC/MS to assess brain tracer distribution in preclinical, in vivo receptor occupancy studies: Dopamine D2, serotonin 2A and NK-1 receptors as examples

Life Sciences

Volumn 78, Issue 4, 2005, Pages 340-346

  Chernet, Eyassu ^a   Martin, Laura J ^a   Li, Dominic ^a   Need, Anne B ^a   Barth, Vanessa N ^a   Rash, Karen S ^a   Phebus, Lee A ^a  

^a ELI LILLY AND COMPANY   (United States)

Author keywords

5 HT2A; Clozapine; D2; Dopamine; Gerbil; GR205171; Haloperidol; In vivo binding; Liquid chromatography; Mass spectroscopy; MDL 100907; MK 869; Neurokinin; NK 1; Olanzapine; Raclopride; Rat; Receptor occupancy; Serotonin

Indexed keywords

ALPHA (2,3 DIMETHOXYPHENYL) 1 [2 (4 FLUOROPHENYL)ETHYL] 4 PIPERIDINEMETHANOL; CLOZAPINE; DOPAMINE 2 RECEPTOR; HALOPERIDOL; NEUROKININ 1 RECEPTOR; NEUROLEPTIC AGENT; OLANZAPINE; RACLOPRIDE; SEROTONIN 2A RECEPTOR; TRACER; VOFOPITANT;

ANIMAL EXPERIMENT; ANIMAL TISSUE; ARTICLE; BINDING SITE; BRAIN; CONTROLLED STUDY; DOSE RESPONSE; ISOTOPE LABELING; LIQUID CHROMATOGRAPHY; MASS SPECTROMETRY; MEASUREMENT; NONHUMAN; PROTEIN LOCALIZATION; RAT; RECEPTOR DENSITY; RECEPTOR OCCUPANCY;

ANIMALS; ANTIPSYCHOTIC AGENTS; BENZODIAZEPINES; BRAIN; CHROMATOGRAPHY, HIGH PRESSURE LIQUID; CLOZAPINE; DOPAMINE ANTAGONISTS; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG ADMINISTRATION ROUTES; DRUG EVALUATION, PRECLINICAL; FLUOROBENZENES; GERBILLINAE; HALOPERIDOL; MALE; MASS SPECTROMETRY; MORPHOLINES; PIPERIDINES; RACLOPRIDE; RATS; RECEPTOR, SEROTONIN, 5-HT2A; RECEPTORS, DOPAMINE D2; RECEPTORS, NEUROKININ-1; SEROTONIN ANTAGONISTS; TETRAZOLES;

ANIMALIA; GERBILLINAE;

EID: 27744530843     PISSN: 00243205     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.lfs.2005.04.075     Document Type: Article

References (26)

1. M. Bergstrom, K.J. Fasth, G. Kilpatrick, P. Ward, K.M. Cable, M.D. Wipperman, D.R. Sutherland, and B. Langstrom Brain uptake and receptor binding of two [11C]labelled selective high affinity NK1-antagonists, GR203040 and GR205171-PET studies in rhesus monkey Neuropharmacology 39 4 2000 664 670
2. H.D. Burns, T.G. Hamill, W.-S. Eng, and R. Hargreaves PET ligands for assessing receptor occupancy in vivo Annual Reports in Medicinal Chemistry 2001 36267 36276
3. L. Farde, F.A. Wiesel, C. Halldin, and G. Sedvall Central D2-dopamine receptor occupancy in schizophrenic patients treated with antipsychotic drugs Archives Of General Psychiatry 45 1 1988 71 76
4. N. Ginovart, W. Sun, A.A. Wilson, S. Houole, and S. Kapur Quantitative validation of a intracerebral β-sensitive microprobe system to determine in vivo drug-induced receptor occupancy using [11C]raclopride in rats Synapse 52 2004 89 99
5. B.D. Gitter, D.C. Waters, R.F. Bruns, N.R. Mason, J.A. Nixon, and J.J. Howbert Species differences in affinities of non-peptide antagonists for substance P receptors European Journal of Pharmacology 197 2-3 1991 237 238
6. G. Grunder, F. Yokoi, S.J. Offord, H.T. Ravert, R.F. Dannals, J.K. Salzmann, S. Szymanski, P.D. Wilson, D.R. Howard, and D.F. Wong Time course of 5-HT2A receptor occupancy in the human brain after a single oral dose of the putative antipsychotic drug MDL 100,907 measured by positron emission tomography Neuropsychopharmacology 17 3 1997 175 185
7. R. Hargreaves Imaging substance P receptors (NK1) in the living human brain using positron emission tomography Journal of Clinical Psychiatry 63 Suppl. 11 2002 18 24
8. S. Hume, R. Gunn, and T. Jones Pharmacological constraints associated with positron emission tomographic scanning of small laboratory animals European Journal of Nuclear Medicine 25 2 1998 173 176
9. O. Inoue, K. Kobayashi, R. Hosoi, M. Yamaguchi, and A. Gee Discrepancies in apparent dopamine D2 receptor occupancy between 3H-raclopride and 3H-N-methylspiperone Journal of Neural Transmission 106 11-12 1999 1099 1104
10. R. Invernizzi, F. Morali, L. Pozzi, and R. Samanin Effects of acute and chronic clozapine on dopamine release and metabolism in the striatum and nucleus accumbens of conscious rats British Journal of Pharmacology 100 4 1990 774 778
11. K. Ito, Y. Sawada, Y. Sugiyama, M. Hanano, and T. Iga Kinetic evaluation for measurement of in vivo receptor occupancy by psychotropic drug in brain: implication for human studies Chemical and Pharmaceutical Bulletin 39 7 1991 1813 1819
12. H. Ito, S. Nyberg, C. Halldin, C. Lundkvist, and L. Farde PET imaging of central 5-HT2A receptors with carbon-11-MDL 100,907 Journal of Nuclear Medicine 39 1 1998 208 214
13. M.P. Johnson, B.W. Siegel, and A.A. Carr [3H]MDL 100,907: a novel selective 5-HT2A receptor ligand Naunyn-Schmiedebergs Archives of Pharmacology 354 2 1996 205 209
14. S.M.D.P.F. Kapur, R.B.M.D.F. Zipursky, and G.M.D.P.F. Remington Clinical and theoretical implications of 5-HT2 and D2 receptor occupancy of clozapine, risperidone, and olanzapine in schizophrenia American Journal of Psychiatry 156 2 1999 286 293 February
15. S. Kapur, S.C. Barsoum, and P. Seeman Dopamine D2 receptor blockade by haloperidol: 3H-raclopride reveals much higher occupancy than EEDQ Neuropsychopharmacology 23 5 2000 595 598
16. S. Kapur, S.C. Vanderspek, B.A. Brownlee, and J.N. Nobrega Antipsychotic dosing in preclinical models is often unrepresentative of the clinical condition: a suggested solution based on in vivo occupancy Journal of Pharmacology and Experimental Therapeutics 305 2 2003 625 631
17. J.H. Kehne, B.M. Baron, A.A. Carr, S.F. Chaney, J. Elands, D.J. Feldman, R.A. Frank, P.L. van Giersbergen, T.C. McCloskey, M.P. Johnson, D.R. McCarty, M. Poirot, Y. Senyah, B.W. Siegel, and C. Widmaier Preclinical characterization of the potential of the putative atypical antipsychotic MDL 100,907 as a potent 5-HT2A antagonist with a favorable CNS safety profile Journal of Pharmacology and Experimental Therapeutics 277 2 1996 968 981
18. C. Kohler, H. Hall, S.O. Ogren, and L. Gawell Specific in vitro and in vivo binding of 3H-raclopride. A potent substituted benzamide drug with high affinity for dopamine D-2 receptors in the rat brain Biochemical Pharmacology 34 13 1985 2251 2259
19. N.A. Moore, N.C. Tye, M.S. Axton, and F.C. Risius The behavioral pharmacology of olanzapine, a novel "atypical" antipsychotic agent Journal of Pharmacology and Experimental Therapeutics 262 2 1992 545 551
20. C.A. Stockmeier, J.J. DiCarlo, Y. Zhang, P. Thompson, and H.Y. Meltzer Characterization of typical and atypical antipsychotic drugs based on in vivo occupancy of serotonin2 and dopamine2 receptors Journal of Pharmacology and Experimental Therapeutics 266 3 1993 1374 1384
21. G.B. Varty, M.E. Cohen-Williams, C.A. Morgan, U. Pylak, R.A. Duffy, E. L.J., G.J. Carey, and V.L. Coffin The gerbil elevated plus-maze II: anxiolytic-like effects of selective neurokinin NK1 receptor antagonists Neuropsychopharmacology 27 3 2002 371 379
22. G.B. Varty, M.E. Cohen-Williams, and J.C. Hunter The antidepressant-like effects of neurokinin NK1 receptor antagonists in a gerbil tail suspension test Behavioural Pharmacology 14 1 2003 87 95
23. M.-L.G. Wadenberg, S. Kapur, A. Soliman, C. Jones, and F. Vaccarino Dopamine D2 receptor occupancy predicts catalepsy and the suppression of conditioned avoidance response behavior in rats Psychopharmacology (Berlin) 150 4 2000 422 429
24. M.-L.G. Wadenberg, A. Soliman, S.C. Vander Spek, and S. Kapur Dopamine D2 receptor occupancy is a common mechanism underlying animal models of antipsychotics and their clinical effects Neuropsychopharmacology 25 5 2001 633 641
25. P.C. Waldmeier, and L. Maitre Clozapine: reduction of the initial dopamine turnover increase by repeated treatment European Journal of Pharmacology 38 1 1976 197 203
26. W. Zhang, and F.P. Bymaster The in vivo effects of olanzapine and other antipsychotic agents on receptor occupancy and antagonism of dopamine D1, D2, D3, 5HT2A and muscarinic receptors Psychopharmacology (Berlin) 141 3 1999 267 278